Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H11NO5 |
Molecular Weight | 273.2408 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O
InChI
InChIKey=MIQPIUSUKVNLNT-UHFFFAOYSA-N
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00323Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00323
Curator's Comment: Description was created based on several sources, including
Tolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa. The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome. Tolcapone is used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies. Tolcapone is sold under the brand name Tasmar.
CNS Activity
Sources: https://www.drugs.com/pro/tolcapone.html
Curator's Comment: Tolcapone enters the CNS to a minimal extent, but has been shown to inhibit central COMT activity in animals.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2023 |
151.0 nM [IC50] | ||
Target ID: CHEMBL612255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24148818 |
29.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Tasmar Approved UseTASMAR is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should
ordinarily be used in patients with Parkinson’s disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury
and because TASMAR, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from TASMAR. Launch Date1998 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.7 mg/L |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.6 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
20.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.1 mg × h/L |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.5 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
67.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.7 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768073 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
TOLCAPONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.1% |
unknown, unknown |
TOLCAPONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 3 times / day multiple, oral Overdose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: |
healthy, 55 - 75 Health Status: healthy Age Group: 55 - 75 Sex: M+F Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 33%) Sources: Vomiting (severe, 33%) |
800 mg 3 times / day multiple, oral Overdose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: |
healthy Health Status: healthy Sources: |
Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness Sources: |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Acute liver failure, Hepatocellular injury... AEs leading to discontinuation/dose reduction: Acute liver failure (grade 3-5) Sources: Hepatocellular injury (grade 3-5) |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (6%) Sources: |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: ALT increased, Aspartate aminotransferase increased... AEs leading to discontinuation/dose reduction: ALT increased (1.7%) Sources: Aspartate aminotransferase increased (1.7%) |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Somnolence... AEs leading to discontinuation/dose reduction: Somnolence (1%) Sources: |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Hallucinations... AEs leading to discontinuation/dose reduction: Hallucinations (1%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | severe, 33% Disc. AE |
800 mg 3 times / day multiple, oral Overdose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: |
healthy, 55 - 75 Health Status: healthy Age Group: 55 - 75 Sex: M+F Sources: |
Vomiting | severe, 33% Disc. AE |
800 mg 3 times / day multiple, oral Overdose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: |
healthy, 55 - 75 Health Status: healthy Age Group: 55 - 75 Sex: M+F Sources: |
Dizziness | Disc. AE | 800 mg 3 times / day multiple, oral Overdose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: |
healthy Health Status: healthy Sources: |
Acute liver failure | grade 3-5 Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hepatocellular injury | grade 3-5 Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea | 6% Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
ALT increased | 1.7% Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Aspartate aminotransferase increased | 1.7% Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Somnolence | 1% Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hallucinations | 1% Disc. AE |
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
yes [Km 7 uM] | |||
Page: 4.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor. | 2000 Apr 15 |
|
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. | 2000 Jun |
|
Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. | 2000 Sep |
|
A preclinical re-evaluation of the safety profile of tolcapone. | 2001 |
|
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. | 2001 |
|
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. | 2001 |
|
Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. | 2001 Aug 15 |
|
Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone. | 2001 Feb |
|
[Pharmacological treatments of Parkinson's disease]. | 2001 Feb |
|
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. | 2001 Feb |
|
Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. | 2001 Jul-Aug |
|
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease. | 2002 |
|
Characterization of catechol glucuronidation in rat liver. | 2002 Feb |
|
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. | 2002 Mar 1 |
|
Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. | 2002 Nov |
|
Effects of entacapone and tolcapone on mitochondrial membrane potential. | 2002 Oct 18 |
|
Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. | 2003 |
|
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. | 2003 Aug |
|
The relevance of preclinical studies for the treatment of Parkinson's disease. | 2003 Feb |
|
Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. | 2003 Jul-Aug |
|
Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. | 2003 Mar |
|
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. | 2003 Sep |
|
Assessment of catechol induction and glucuronidation in rat liver microsomes. | 2004 Dec |
|
Safety and tolerability of COMT inhibitors. | 2004 Jan 13 |
|
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. | 2004 Oct 18 |
|
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. | 2004 Sep |
|
Oxidative stress mediated idiosyncratic drug toxicity. | 2005 |
|
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. | 2005 Apr |
|
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. | 2005 Dec 13 |
|
Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. | 2005 Jan |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases. | 2005 Jun 1 |
|
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. | 2005 May |
|
Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. | 2005 Nov |
|
Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. | 2007 |
|
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. | 2007 Jan |
|
Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. | 2007 Nov-Dec |
|
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. | 2007 Sep |
Sample Use Guides
The initial dose of TASMAR is always 100 mg three times per day. The recommended daily dose of TASMAR is also 100 mg tid.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10064789
When using a fixed amount of total protein (2 ug/ml), but variable concentrations of COMT, the inhibitory potency of tolcapone upon S- and MB-COMT activity in the rat brain was in the low nM range (IC50's of 2 and 3 nM, respectively), whereas in rat liver the IC50 values for tolcapone against liver MB- and S-COMT (IC50's of 123 and 795 nM, respectively) were markedly higher than those observed in the brain. By contrast, when inhibition studies were performed with a fixed concentration of COMT (15 nM), tolcapone was found to be endowed with the same potency (in the low nM range) in inhibiting S- and MB-COMT from both brain and liver.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
TASMAR (AUTHORIZED: PARKINSON DISEASE)
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
NDF-RT |
N0000175756
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
WHO-ATC |
N04BX01
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
WHO-VATC |
QN04BX01
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
LIVERTOX |
NBK548573
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
FDA ORPHAN DRUG |
413913
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
NDF-RT |
N0000175757
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
||
|
NCI_THESAURUS |
C38149
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB11151MIG
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
100000089195
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
72937
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | RxNorm | ||
|
FF-11
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
4659569
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
m10938
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | Merck Index | ||
|
1670207
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
DB00323
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
DTXSID3023685
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
TOLCAPONE
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
6873
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
CHEMBL1324
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
63630
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
134308-13-7
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
6646
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
Tolcapone
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
2697
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
CIF6334OLY
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
CIF6334OLY
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
C066340
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY | |||
|
C47762
Created by
admin on Wed Apr 02 09:33:04 GMT 2025 , Edited by admin on Wed Apr 02 09:33:04 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)